Document is current
Any future updates will be listed below
-
Authors
Font, Octavi
Torrents-Barrena, Jordina
Royo, Dídac
García, Sandra Banderas https://orcid.org/0000-0002-3641-3806
Zarranz-Ventura, Javier
Bures, Anniken
Salinas, Cecilia
Zapata, Miguel Ángel
-
Funding
Funding for this research was provided by:
Universitat Autònoma de Barcelona
- License Information
-
More Information
Article History
Received: 4 June 2021
Revised: 15 March 2022
Accepted: 31 March 2022
First Online: 14 May 2022
Declarations
:
: Optretina is a company supervised by the ethics committee of the Vall d’Hebron Hospital in Barcelona, who approved this clinical trial (Study code PR(OPT)370/2019).
: Patient’s informed consent was exempted because of the retrospective nature of the study, using fully anonymized retinal images.
: MA. Zapata is the founding member and medical director of Optretina. D. Royo is founding partner and technical director of the company. O. Font is employed in Optretina and A. Bures and C. Salinas work as fundoscopy reader in the company. The authors declare no other direct financial conflicts of interest as individuals.
